Athersys Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Athersys stock.
View analyst ratings for Athersys or view top-rated stocks.

Wall Street analysts have given Athersys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Athersys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Athersys is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Athersys.

Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.05.
View Athersys' earnings history.

Athersys' stock was trading at $1.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATHX shares have increased by 27.3% and is now trading at $1.63.
View which stocks have been most impacted by COVID-19.

3 brokerages have issued 12 month price targets for Athersys' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Athersys' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 206.7% from the stock's current price.
View analysts' price targets for Athersys or view top-rated stocks among Wall Street analysts.

2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Athersys include Arcutis Biotherapeutics (ARQT), NGM Biopharmaceuticals (NGM), DiaMedica Therapeutics (DMCAF), Avid Bioservices (CDMO), Zealand Pharma A/S (ZEAL), Stoke Therapeutics (STOK), Northwest Biotherapeutics (NWBO), ImmunoGen (IMGN), Nurix Therapeutics (NRIX), MacroGenics (MGNX), Innoviva (INVA), Edgewise Therapeutics (EWTX), Day One Biopharmaceuticals (DAWN), Vectura Group (VEGPF) and Shattuck Labs (STTK).
View all of ATHX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Athersys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.40%), JPMorgan Chase & Co. (1.53%), Geode Capital Management LLC (1.38%), Northern Trust Corp (0.87%), Citigroup Inc. (0.34%) and Bank of New York Mellon Corp (0.32%). Company insiders that own Athersys stock include John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends for Athersys.

ATHX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Russell Investments Group Ltd., Morgan Stanley, Northern Trust Corp, Goldman Sachs Group Inc., Alliancebernstein L.P., AQR Capital Management LLC, and Nuveen Asset Management LLC. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr.
View insider buying and selling activity for Athersys or view top insider-selling stocks.

ATHX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., UBS Group AG, Citigroup Inc., Rafferty Asset Management LLC, Geode Capital Management LLC, BlackRock Inc., Squarepoint Ops LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Athersys or or view top insider-buying stocks.

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATHX stock can currently be purchased for approximately $1.63.

Athersys has a market capitalization of $362.00 million and generates $1.44 million in revenue each year. The biopharmaceutical company earns $-78,760,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

Athersys employs 97 workers across the globe.

The official website for Athersys is www.athersys.com.

Athersys is headquartered at 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]